-
41
Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
Published 2012-01-01Subjects: Get full text
Article -
42
Epidemiological and microbiological profile of infective keratitis in Ahmedabad
Published 2012-01-01Subjects: Get full text
Article -
43
Retina spotlight: Diabetic retinopathy - Preferred practice patterns
Published 2017-01-01Subjects: Get full text
Article -
44
-
45
Analysis of photoastigmatic keratectomy with the cross-cylinder ablation
Published 2012-01-01Subjects: Get full text
Article -
46
Ophthalmic contributions of Raja Serfoji II (1798-1832)
Published 2012-01-01Subjects: Get full text
Article -
47
Magnetic resonance imaging for the ophthalmologist: A primer
Published 2012-01-01Subjects: Get full text
Article -
48
Bilateral acute macular neuroretinopathy in a postpartum, otherwise healthy female: A case report
Published 2012-01-01Subjects: Get full text
Article -
49
Desferrioxamine-related ocular toxicity: A case report
Published 2012-01-01Subjects: Get full text
Article -
50
-
51
-
52
Candida albicans interface infection after deep anterior lamellar keratoplasty
Published 2012-01-01Subjects: Get full text
Article -
53
Intralesional bleomycin for the treatment of periocular capillary hemangiomas
Published 2012-01-01Subjects: Get full text
Article -
54
Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019
Published 2022-04-01“…The mean BCVA before and after treatment for both drugs respectively 0.19 min and 0.21 min was statistically correlated (p = 0.000). For patients under Lucentis, the mean BCVA before and after medication was 0.20 min– 0.24 min and 0.19– 0.19 min for those who used Avastin. …”
Get full text
Article -
55
Studies on sustained release platforms for delivery of therapeutic agents to the posterior segment of the eye
Published 2017“…Trans-scleral transport of Lucentis from different liposome-encapsulated formulations was compared with trans-scleral transport of bare-Lucentis and found to be slowed down in the case of encapsulated formulations. …”
Get full text
Thesis -
56
Study on ocular drug delivery system for treatment of posterior segment eye diseases
Published 2014“…ELISA and microBCA tests were carried out and results proved that degradation of Lucentis occurred over the 10 weeks of incubation. …”
Get full text
Final Year Project (FYP) -
57
Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
Published 2017-01-01“…A loading dose of three monthly Ranibizumab (Lucentis®) injections were given to the recruited subjects. …”
Get full text
Article -
58
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
Published 2018-10-01“…It is important for clinicians to have a clear understanding about ophthalmic biosimilars before the industry brings these molecules to the mainstream clinical use globally.Keywords: biosimilar, Razumab®, Lucentis®, Eylea®, ophthalmology…”
Get full text
Article -
59
Effect of Ranibizumab with macular grid pattern photocoagulation for macular edema caused by branch retinal vein occlusion
Published 2016-04-01“…AIM:To evaluate the effect of Ranibizumab(lucentis)combined with macular grid pattern photocoagulation in the treatment of macular edema caused by branch retinal vein occlusion(BRVO). …”
Get full text
Article -
60
The effects of anti-VEGF drugs on the retinal pigment epithelium and inner segment after intravitreal injection in the monkeys
Published 2016-06-01“…But at 7d, both Lucentis and Eylea have the same effect on reducing VEGF expression level in the RPE and inner segment.…”
Get full text
Article